{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biomarker+Testing&page=15", "query": { "intervention": "Biomarker Testing", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 808, "total_pages": 81, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biomarker+Testing&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biomarker+Testing&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T00:30:32.978Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03321955", "title": "Ziconotide as First-Line IDT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Neuropathic Pain" ], "interventions": [ { "name": "Ziconotide 100 MCG(microgram)/ML Intrathecal Solution", "type": "DRUG" }, { "name": "Quantitative sensory testing", "type": "DIAGNOSTIC_TEST" }, { "name": "Serum markers: Interleukin-1, Interleukin-6, and tumor necrosis factor", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Albany Medical College", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2016-11-03", "completion_date": "2020-12-30", "has_results": false, "last_update_posted_date": "2021-01-12", "last_synced_at": "2026-10-22T00:30:32.978Z", "location_count": 1, "location_summary": "Albany, New York", "locations": [ { "city": "Albany", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03321955" }, { "nct_id": "NCT06766435", "title": "Evaluation of the Abbott i-STAT TBI Biomarker Test", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Traumatic Brain Injury" ], "interventions": [ { "name": "i-STAT TBI Test", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2025-01-30", "completion_date": "2026-05-30", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-22T00:30:32.978Z", "location_count": 3, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06766435" }, { "nct_id": "NCT03013998", "title": "Study of Biomarker-Based Treatment of Acute Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Previously Untreated Relapsed Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Samalizumab (BAML-16-001-S1)", "type": "BIOLOGICAL" }, { "name": "BI 836858 (BAML-16-001-S2)", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Daunorubicin (BAML-16-001-S1)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S1)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S2)", "type": "DRUG" }, { "name": "AG-221 (BAML-16-001-S3)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S3)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S4)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S4)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S5)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S5)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Daunorubicin (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Pevonedistat (BAML-16-001-S9)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S9)", "type": "DRUG" }, { "name": "AG-120 (BAML-16-001-S16)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S16)", "type": "DRUG" }, { "name": "Gilteritinib (BAML-16-001-S8 Group 1)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S8 Group 1)", "type": "DRUG" }, { "name": "AZD5153 (BAML-16-001-S10)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S10)", "type": "DRUG" }, { "name": "TP-0903 (BAML-16-001-S14)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S14)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "AZD5991 (BAML-16-001-S18)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S18)", "type": "DRUG" }, { "name": "SNDX-5613 (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Gilteritinib (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S12 Arm A)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S12 Arm A)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S12 Arm B)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S12 Arm B)", "type": "DRUG" }, { "name": "ZE46-0134 (BAML-16-001-S21 Group 1)", "type": "DRUG" }, { "name": "ficlatuzumab (BAML-16-001-S24)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S24)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S24)", "type": "DRUG" }, { "name": "ZE46-0134 (BAML-16-001-S21 Group 2)", "type": "DRUG" }, { "name": "Bleximenib (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Daunorubicin or Idarubicin (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Placebo (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Revumenib (BAML-16-001-S26/HO177)", "type": "DRUG" }, { "name": "Placebo (BAML-16-001-S26/HO177)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Beat AML, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3000, "start_date": "2016-11", "completion_date": "2032-12", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-22T00:30:32.978Z", "location_count": 31, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03013998" }, { "nct_id": "NCT03269721", "title": "COPD-Related Physiology and the Brain", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pulmonary Disease, Chronic Obstructive (COPD)", "Cognitive Impairment" ], "interventions": [ { "name": "Neuropsychological Assessment", "type": "BEHAVIORAL" }, { "name": "Spirometry", "type": "PROCEDURE" }, { "name": "Arterial Blood Gas", "type": "PROCEDURE" }, { "name": "Diffusion Capacity of the Lung for Carbon Monoxide", "type": "PROCEDURE" }, { "name": "6 Minute Walk Test", "type": "DIAGNOSTIC_TEST" }, { "name": "Systemic Vascular Measures", "type": "PROCEDURE" }, { "name": "Blood Biomarkers", "type": "BIOLOGICAL" }, { "name": "Symptom Questionnaire Measures", "type": "BEHAVIORAL" }, { "name": "Brain MRI", "type": "PROCEDURE" } ], "intervention_types": [ "BEHAVIORAL", "PROCEDURE", "DIAGNOSTIC_TEST", "BIOLOGICAL" ], "sponsor": "Karin Hoth", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "30 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "30 Years to 85 Years" }, "enrollment_count": 170, "start_date": "2017-05-01", "completion_date": "2025-04-30", "has_results": false, "last_update_posted_date": "2025-12-24", "last_synced_at": "2026-10-22T00:30:32.978Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT03269721" }, { "nct_id": "NCT03012958", "title": "Utility of Lung Clearance Index Score as a Noninvasive Marker of Deployment Lung Disease", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bronchiolitis", "Pneumonitis", "Dyspnea" ], "interventions": [ { "name": "Lung clearance index (LCI)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "National Jewish Health", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2014-07", "completion_date": "2018-05", "has_results": false, "last_update_posted_date": "2021-01-08", "last_synced_at": "2026-10-22T00:30:32.978Z", "location_count": 1, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03012958" }, { "nct_id": "NCT05795634", "title": "Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Mild Cognitive Impairment", "Alzheimer Disease" ], "interventions": [ { "name": "Trier Social Stress Test", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 240, "start_date": "2023-03-01", "completion_date": "2029-03-01", "has_results": false, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-10-22T00:30:32.978Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05795634" }, { "nct_id": "NCT07640152", "title": "Fermented Foods and Bowel Health in SCI", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Spinal Cord Injury" ], "interventions": [ { "name": "fermented foods", "type": "OTHER" }, { "name": "Control diet", "type": "OTHER" }, { "name": "Sitz Marker Test", "type": "DEVICE" } ], "intervention_types": [ "OTHER", "DEVICE" ], "sponsor": "Ohio State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 44, "start_date": "2026-08-01", "completion_date": "2029-07-31", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-10-22T00:30:32.978Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07640152" }, { "nct_id": "NCT04928014", "title": "Validation of a Tear-based Screening Assay for Breast Cancer", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Healthy", "Breast Cancer", "Breast Cancer Female", "Health Care Utilization", "Health Knowledge, Attitudes, Practice", "Health Personnel Attitude", "Health Care Acceptability" ], "interventions": [ { "name": "Schirmer Strip", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Namida Lab", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "FEMALE", "summary": "18 Years to 100 Years · Female only" }, "enrollment_count": 205, "start_date": "2021-06-01", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2023-07-03", "last_synced_at": "2026-10-22T00:30:32.978Z", "location_count": 1, "location_summary": "Fayetteville, Arkansas", "locations": [ { "city": "Fayetteville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04928014" }, { "nct_id": "NCT06986135", "title": "The Effect of Breathing on Cognitive Performance and Stress", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stress", "Acute Stress Reaction", "Breathing Techniques", "Cognitive Performance" ], "interventions": [ { "name": "Box Breathing", "type": "OTHER" }, { "name": "Prolonged Exhalation", "type": "OTHER" }, { "name": "Normal Breathing", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Texas State University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "18 Years to 39 Years" }, "enrollment_count": 66, "start_date": "2024-08-01", "completion_date": "2025-05-01", "has_results": false, "last_update_posted_date": "2025-05-22", "last_synced_at": "2026-10-22T00:30:32.978Z", "location_count": 1, "location_summary": "San Marcos, Texas", "locations": [ { "city": "San Marcos", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06986135" }, { "nct_id": "NCT03063632", "title": "Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Myxoid Liposarcoma", "Metastatic Round Cell Liposarcoma", "Metastatic Synovial Sarcoma", "Recurrent Mycosis Fungoides and Sezary Syndrome", "Refractory Mycosis Fungoides and Sezary Syndrome", "Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7", "Unresectable Synovial Sarcoma" ], "interventions": [ { "name": "Interferon Gamma-1b", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 28, "start_date": "2017-12-14", "completion_date": "2023-03-14", "has_results": true, "last_update_posted_date": "2023-10-25", "last_synced_at": "2026-10-22T00:30:32.978Z", "location_count": 7, "location_summary": "Palo Alto, California • Miami, Florida • Boston, Massachusetts + 4 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03063632" } ] }